Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'.
作者信息
Dankner Matthew, Rose April A N
机构信息
Goodman Cancer Research Centre, McGill University, Montreal, QC, Canada.
Department of Medicine, McGill University, Montreal, QC, Canada.
出版信息
Br J Cancer. 2018 May;118(9):1276-1277. doi: 10.1038/s41416-018-0012-2. Epub 2018 Mar 22.
Abstract
摘要
相似文献
1
Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'.
Br J Cancer. 2018 May;118(9):1276-1277. doi: 10.1038/s41416-018-0012-2. Epub 2018 Mar 22.
2
Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''.
Br J Cancer. 2018 May;118(9):1278-1279. doi: 10.1038/s41416-018-0040-y. Epub 2018 Mar 22.
3
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3.
4
BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: a meta-analysis.
Chin Med Sci J. 2014 Dec;29(4):197-203. doi: 10.1016/s1001-9294(14)60070-5.
5
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25.
6
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.
7
Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
PLoS One. 2016 Jun 17;11(6):e0157830. doi: 10.1371/journal.pone.0157830. eCollection 2016.
8
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.
9
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21.
10
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9.
引用本文的文献
1
Multidrug resistance in the standardized treatment of colon cancer harboring a rare fibrosarcoma B-type (BRAF) p.N581I mutation: a case report.
Front Oncol. 2023 Jul 14;13:1175693. doi: 10.3389/fonc.2023.1175693. eCollection 2023.
本文引用的文献
1
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Oncogene. 2018 Jun;37(24):3183-3199. doi: 10.1038/s41388-018-0171-x. Epub 2018 Mar 15.
2
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3.
3
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2.
4
BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.
J Clin Oncol. 2017 Aug 10;35(23):2624-2630. doi: 10.1200/JCO.2016.71.4394. Epub 2017 May 9.
5
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
J Clin Oncol. 2015 Mar 1;33(7):692-700. doi: 10.1200/JCO.2014.59.4812. Epub 2015 Jan 20.
6
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.
7
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8.
8
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Cell. 2004 Mar 19;116(6):855-67. doi: 10.1016/s0092-8674(04)00215-6.
Zotero 插件